<DOC>
	<DOCNO>NCT02212730</DOCNO>
	<brief_summary>This study examine effect treatment neoadjuvant antibody pembrolizumab ( MK-3475 ) tumor participants renal cell cancer ( RCC ) . The primary hypothesis pembrolizumab well tolerated participant undergo RCC tumor resection ; pembrolizumab stimulate 2-fold great increase intratumoral lymphocytic infiltration least 30 % participant RCC .</brief_summary>
	<brief_title>A Study Evaluating Effect Pembrolizumab ( MK-3475 ) Participants With Renal Cell Cancer ( MK-3475-031 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Have newly diagnose RCC , primary tumor diameter 4 cm ( &gt; = T1b ) , previously treat , candidate operative tumor resection Be willing able undergo pretreatment baseline imageguided core biopsy primary RCC Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Demonstrate adequate organ function Female breast feeding , postmenopausal surgically sterile ; demonstrate nonpregnant state , agree use two acceptable method birth control throughout trial , 120 day last dose treatment Male female partner childbearing potential agrees use adequate method contraception throughout study , 120 day last dose treatment last blood draw . Is currently participate , participate study investigational agent device within 4 week prior first dose study therapy Has diagnosis immunosuppression receive systemic steroid therapy , form immunosuppressive therapy within 4 week prior first dose study therapy Has prior chemotherapy , target small molecule , radiation therapy treatment RCC Has know additional ( RCC ) malignancy progress require active treatment Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Has active , documented history autoimmune disease , exception vitiligo resolve childhood asthma/atopy Has active , noninfectious pneumonitis Has active infection require systematic therapy Is receive anticoagulant therapy , exception low dosage aspirin Has severe cardiovascular disease symptomatic ischemic heart disease Has hepatic decompensation Has uncontrolled thyroid dysfunction Has uncontrolled diabetes mellitus Has know psychiatric substance abuse disorder Female pregnant breastfeeding Is expect conceive child within project maximum duration trial , extend 120 day last dose treatment last blood draw Has receive prior therapy antibody drug ( include ipilimumab ) specifically target Tcell costimulation checkpoint pathway Has know history human immunodeficiency virus ( HIV ) Has know active hepatitis B C Has receive live vaccine within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>